What Was Approved
The decision came, and it was yes.
The FDA approved centanafadine, marketed as SIMTRIYO by Otsuka, for attention-deficit/hyperactivity disorder in adults and pediatric patients. The label covers patients aged 6 years and older who weigh more than 20 kilograms, roughly 44 pounds.
That weight threshold is the detail most coverage will skip, and it is the one that determines whether a specific child is eligible. A 6-year-old below 20 kilograms does not qualify under this label even though they meet the age criterion.
Centanafadine is described as a first-in-class norepinephrine-dopamine-serotonin reuptake inhibitor, a mechanism no previously approved ADHD medication uses.
What Changed Since MedicalDaily's Previous Report
MedicalDaily previously reported that the FDA was expected to rule on centanafadine on July 24, describing what approval would mean for the estimated 15.5 million adults and 7 million children and adolescents diagnosed with ADHD in the United States.
What is different now is that the decision is made and a label exists. The question has shifted from whether patients will have this option to who specifically qualifies and what a clinician conversation should cover.
Why This Matters for Families
The people this approval is aimed at are not families doing well on a stimulant. It is aimed at three groups who have had limited options.
Families whose child cannot tolerate stimulants because of appetite suppression, sleep disruption, mood effects or cardiovascular concerns. Patients who tried existing non-stimulants, primarily atomoxetine, guanfacine and clonidine, without adequate benefit. And households where a controlled substance is a practical problem, whether because of a family history of substance use disorder or because of the prescribing restrictions and pharmacy shortages that have made stimulants hard to obtain in recent years.
For that last group, a non-controlled option removes the monthly prescription requirement and the pharmacy hunt that has defined the last few years for many families.
How It Differs From What Exists
Stimulants remain the most effective ADHD medications on average, and this approval does not change first-line treatment guidance.
The existing non-stimulants work differently from each other. Atomoxetine primarily affects norepinephrine. Guanfacine and clonidine are alpha-2 agonists originally developed for blood pressure. Centrafadine's mechanism touches three neurotransmitter systems rather than one.
Whether that translates into better outcomes for a specific patient is not something a mechanism explains. Non-stimulants generally take weeks rather than hours to show effect, unlike stimulants, and families should expect a slower assessment period.
What the Trials Showed
Otsuka's phase 3 program spanned ages 4 to 55. Pediatric and adolescent trials met week-6 efficacy endpoints on the ADHD Rating Scale versus placebo in high-dose cohorts. Adult trials showed statistically significant symptom reductions at both 200 mg and 400 mg compared with placebo by week 6 on an investigator-rated scale.
Post hoc analyses suggested improvements in executive function domains including time management, planning and prioritization, task initiation and completion, and working memory, along with emotional dysregulation.
Two limitations belong here rather than at the end. Post hoc analyses are exploratory and generate hypotheses rather than establishing effects. And a six-week endpoint tells you about short-term response, not about durability over the years most patients take these medications. Full study results are expected at an upcoming scientific meeting.
Reported Side Effects
In the clinical program, adverse events reported in children and adolescents included decreased appetite, nausea, rash, fatigue, abdominal pain and somnolence. In adults, decreased appetite and headache were reported.
Decreased appetite appearing in both groups is worth noting, because appetite suppression is one of the main reasons families move away from stimulants in the first place. A family switching specifically for that reason should ask the prescriber how the two compare.
The approved prescribing information is the authoritative source for the complete safety profile, including any warnings, and families should review it with a clinician rather than relying on a summary.
Who Should Not Assume This Is for Them
A patient doing well on current treatment has no reason to switch. Changing a working ADHD regimen carries real cost in school or work disruption during the transition.
Children under 6, and children 6 or older weighing 20 kilograms or less, are outside the label. Adults with cardiovascular conditions, seizure history, or who take other medications affecting serotonin should raise those specifically, since reuptake inhibitors can interact with antidepressants and other agents.
ADHD medication of any kind works best alongside behavioral support, school accommodations, and organizational strategies. No medication substitutes for those.
What to Ask a Clinician
Useful questions include whether a trial of this medication makes sense given what has already been tried, how long to wait before judging whether it works, what to monitor at home, and how it would interact with current medications.
For a child, ask what the plan is if appetite decreases, and how growth will be monitored. For an adult, ask about timing relative to any antidepressant.
Nobody should stop a current ADHD medication in anticipation of switching. Discontinuation should be managed by the prescriber.
Cost and Access
Newly approved brand-name medications typically face formulary restrictions in the first year, and prior authorization is likely. Ask the prescriber's office to check coverage before the prescription is written rather than discovering the cost at the counter.
Manufacturer copay assistance programs are common for new launches and can substantially reduce cost for commercially insured patients, though they generally exclude Medicare and Medicaid. Patients denied coverage can appeal, and prescribers can document prior treatment failures to support medical necessity.
Availability at retail pharmacies may take time to reach full distribution after approval.
What Happens Next
Otsuka is expected to release full phase 3 results at a scientific meeting, which will allow independent evaluation of the efficacy and safety data beyond the summary information available now. Payers will make formulary decisions over the coming months. MedicalDaily will report the published trial results and coverage developments.
The Bottom Line
The confirmed fact is FDA approval of centanafadine for ADHD in patients 6 and older weighing more than 20 kilograms. The families it most concerns are those who could not tolerate or did not respond to stimulants. The reasonable next step is a clinician conversation rather than a switch. The central uncertainty is long-term effectiveness, since the pivotal endpoints were measured at six weeks.
